interferon - for COVID-19 severe or critically method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.29 [0.05, 1.56]< 10%1 study (1 / -)92.5 %NAnot evaluable crucial-
clinical improvement (time to event analysis only) 3.41 [1.33, 8.73]> 10%1 study (1 / -)99.5 %NAnot evaluable important-
hospital discharge 3.44 [0.64, 18.49]> 10%1 study (1 / -)92.4 %NAnot evaluable important-
hospitalization 1.00 [0.02, 51.94]< 10%1 study (1 / -)50.0 %NAnot evaluable important-
ventilation 0.29 [0.05, 1.56]< 10%1 study (1 / -)92.5 %NAnot evaluable important-
ICU admission 0.37 [0.14, 1.00]< 10%1 study (1 / -)97.5 %NAnot evaluable non important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 91 91